Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring-Reference-Cited by-同舟云学术

Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring

Published:2021-10-06 Issue:1 Volume:28 Page:45-56
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Stewart Caitlin M.^ORCID,Michaud Laure,Whiting Karissa^ORCID,Nakajima Reiko,Nichols Chelsea,De Frank Stephanie,Hamlin Paul A.^ORCID,Matasar Matthew J.,Gerecitano John F.,Drullinsky Pamela,Hamilton Audrey,Straus David,Horwitz Steven M.,Kumar Anita,Moskowitz Craig H.,Moskowitz Alison,Zelenetz Andrew D.,Rademaker Jurgen,Salles Gilles^ORCID,Seshan Venkatraman,Schöder Heiko^ORCID,Younes Anas,Tsui Dana W.Y.,Batlevi Connie Lee

Funder

Novartis and Janssen

NIH

NCI

ASCO Young Investigator Award

ASH Clinical Scholar Award

Lymphoma Research Foundation Clinical Research Mentoring Program

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. N‐acetyltransferase 10 facilitates tumorigenesis of diffuse large B‐cell lymphoma by regulating AMPK/mTOR signalling through N4‐acetylcytidine modification of SLC30A9;Clinical and Translational Medicine;2024-07

2. Impact of PIK3CA gain and PTEN loss on mantle cell lymphoma biology and sensitivity to targeted therapies;2024-05-02

3. Phase II study of novel orally PI3Kα/δ inhibitor TQ-B3525 in relapsed and/or refractory follicular lymphoma;Signal Transduction and Targeted Therapy;2024-04-17

4. Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas;British Journal of Haematology;2024-03-19

5. Beyond Bruton’s tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody–drug conjugates, CAR T-cells, and novel agents;Journal of Hematology & Oncology;2023-08-25